Louis Taylor appointed Chair of British Patient Capital
Press release
The British Business Bank has appointed Louis Taylor as Chair of British Patient Capital, a commercial subsidiary of the Bank. He takes over from Russ Cummings, who is stepping down after six years on the board which he joined when British Patient Capital was established in 2018. In 2022, Louis Taylor was appointed CEO of the British Business Bank, and continues in this role.
I am immensely proud to have played a part in getting British Patient Capital established from a recommendation which came out of the Patient Capital Review and overseeing its development to become the largest domestic investor in UK venture and venture growth capital. This was only possible because of the fantastic team I worked with at British Patient Capital and its board.
British Patient Capital is a great British success story, both for the venture industry and also because it has demonstrated that it can produce commercially attractive returns. It has an important role to play in encouraging other UK institutional investors to invest in the asset class, to both drive and benefit from the success of our high-growth companies. Having given six years to the organisation, it is in a strong position, and the time is right for me do something fresh.
Russ Cummings outgoing Chair, British Patient Capital
Across its three programmes, British Patient Capital manages assets with a total value of £3,075m Read footnote text 1 and since it was established in 2018, has expanded to include the £425m Future Fund: Breakthrough programme and the £200m Life Sciences Investment Programme.
-
Return to footnote location
1
Includes value of programmes awarded to British Patient Capital and a mandate from a third-party investor.
Russ Cummings has been an outstanding Chair and member of the Board over the past six years. He has made a significant contribution to the growth and success of British Patient Capital, which is now the largest domestic investor in UK venture and venture growth capital and the most active late-stage investor in UK life sciences and deeptech companies. He leaves an impressive legacy and I thank him for his commitment, significant contribution and wish him well.
Louis Taylor Chair, British Patient Capital
New Board Director
Ian Connatty, the Bank’s Deputy Chief Investment Officer, has been appointed to the British Patient Capital board, which he joins as a Director, alongside Hazel Moore, Non-executive Director. He brings with him a wealth of experience in venture capital fund investing and has been with British Patient Capital since it launched in 2018 where he was Managing Director of the Funds business until 2021. After this he was appointed Managing Director, Direct and Co-investment where he established the £425m Future Fund: Breakthrough programme. Ian Connatty was appointed Deputy Chief Investment Officer in December 2023.
New Managing Director, Direct Investments, British Patient Capital
Tom Haywood has been appointed Managing Director, Direct Investments, British Patient Capital. Tom brings more than 15 years’ experience and joined British Patient Capital in 2019. He helped set up its direct investment function and completed Quantexa and Thought Machine as its first direct investments – both of which are now unicorns. Previously he was at Foresight Group and was an investment manager at EcoMachines Ventures. He also co-founded a biotech manufacturing start-up Puridify, which was subsequently sold to GE Healthcare. He began his career in investment banking at Deutsche Bank.
I am delighted to have been appointed to the board, at such an exciting time for British Patient Capital. I look forward to continuing to work with our fantastic team to deliver long-term patient capital to innovative companies in the UK. It is a pleasure to see Tom Haywood appointed Managing Director, Direct Investments, he is a respected professional with a strong track record of investment expertise.
Ian Connatty Deputy Chief Investment Officer, British Patient Capital
Further Information
Notes to editors
About British Patient Capital
British Patient Capital Limited is a wholly owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large-scale businesses. Launched in June 2018, British Patient Capital has more than £3bn of assets under management, investing in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up.
British Business Bank plc and its subsidiary entities are not banking institutions and do not operate as such. They are not authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). A complete legal structure chart for British Business Bank plc and its subsidiaries can be found on the British Business Bank plc website.
British Patient Capital makes commitments and invests on its own behalf and on behalf of third-party investors whose investments British Patient Capital manages.
Latest news
-
Read more about British Patient Capital announces £8m investment into Nuclera as part of a $75m Series C financing round Press release
16 October 2024 -
Read more about British Patient Capital announces investment into Purespring Therapeutics as part of £80m Series B financing round Press release
09 October 2024 -
Read more about British Patient Capital makes €25m commitment to Blume Equity Fund I to support companies tackling climate change Press release
17 September 2024